Date: 2016-01-20 09:39:34Medicine Clinical medicine Immunology Immunosuppressants RTT Biotechnology Autoimmune diseases Arthritis Certolizumab pegol TNF inhibitor UCB Anakinra | | UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include: Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certolAdd to Reading ListSource URL: www.ucb-usa.comDownload Document from Source Website File Size: 539,51 KBShare Document on Facebook
|